These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30660948)

  • 1. Monitoring of heparins in antithrombin-deficient patients.
    Croles FN; Lukens MV; Mulder R; de Maat MPM; Mulder AB; Meijer K
    Thromb Res; 2019 Mar; 175():8-12. PubMed ID: 30660948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
    Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI
    Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombin binding of low molecular weight heparins and inhibition of factor Xa.
    Lin P; Sinha U; Betz A
    Biochim Biophys Acta; 2001 Apr; 1526(1):105-13. PubMed ID: 11287128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
    Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
    Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?
    Ignjatovic V; Summerhayes R; Gan A; Than J; Chan A; Cochrane A; Bennett M; Horton S; Shann F; Lane G; Ross-Smith M; Monagle P
    Thromb Res; 2007; 120(3):347-51. PubMed ID: 17118432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of calcium chloride on anti-Xa activity of heparin and its molecular weight fractions.
    Barrowcliffe TW; Le Shirley Y
    Thromb Haemost; 1989 Nov; 62(3):950-4. PubMed ID: 2556814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the levels of unfractionated and low-molecular-weight heparins in plasma: their effect on thrombin-mediated feedback reactions in vivo. Preliminary results after subcutaneous injection.
    Hemker HC; Béguin S; Bendetowicz AV; Wielders S
    Haemostasis; 1991; 21(4):258-72. PubMed ID: 1665467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic indications of low molecular weight heparins].
    Samama MM; Michaut-Paterno F
    Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1733-43. PubMed ID: 1662941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeated doses of oral and subcutaneous heparins have similar antithrombotic effects in a rat carotid arterial model of thrombosis.
    Hiebert LM; Ping T; Wice SM
    J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):110-6. PubMed ID: 21512111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of exogenous antithrombin on low molecular weight heparin anti-Xa activity assays in a pediatric and young adult leukemia and lymphoma cohort with variable antithrombin levels.
    Schaefer B; Hausfeld A; Martin M; Steele P; Martin J; Reher SR; Lane A; Luchtman-Jones L
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28654. PubMed ID: 32841498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulant effects of low-molecular-weight heparins in healthy cats.
    Alwood AJ; Downend AB; Brooks MB; Slensky KA; Fox JA; Simpson SA; Waddell LS; Baumgardner JE; Otto CM
    J Vet Intern Med; 2007; 21(3):378-87. PubMed ID: 17552440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Very low doses of unfractionated heparin potentiate the anti-Xa activity of low molecular weight heparin (enoxaparin).
    Pèrez-Requejo JL; Lucena-Solano O; Pérez-García M; Santarelli MT
    Thromb Res; 1997 Feb; 85(3):259-65. PubMed ID: 9058500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ratios of anti-factor Xa to antithrombin activities of heparins as determined in recalcified human plasma.
    Schoen P; Lindhout T; Hemker HC
    Br J Haematol; 1992 Jun; 81(2):255-62. PubMed ID: 1322691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH.
    Alban S; Welzel D; Hemker HC
    Semin Thromb Hemost; 2002 Aug; 28(4):369-78. PubMed ID: 12244484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin.
    Hoppensteadt DA; Jeske W; Fareed J; Bermes EW
    Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S57-64. PubMed ID: 7647223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
    Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
    Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy.
    Hansen JB; Sandset PM
    Thromb Res; 1998 Aug; 91(4):177-81. PubMed ID: 9736420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of the extrinsic pathway in the activities of low molecular weight heparins.
    Norrheim L; Abildgaard U; Larsen ML; Lindahl AK
    Thromb Res Suppl; 1991; 14():19-27. PubMed ID: 1658967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.